News Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/12/2025 GMT			5-day change	1st Jan Change
15.05 ^USD	+24.48%		-22.26%	-33.92%

12-05	Top Premarket Decliners	MT
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI

Top Premarket Decliners	12-05	MT
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	11-11	AQ
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	11-11	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	11-06	CI
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results	11-06	AQ
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025	10-30	AQ
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study	10-28	AQ
Quoin Pharmaceuticals Ltd. Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 Month 'Whole Body' Data Update from Ongoing Study	10-28	CI
Quoin Pharmaceuticals, Ltd. announced that it has received $16.450005 million in funding from a group of investors	10-22	CI
Quoin Pharmaceuticals announces U.S. FDA grants orphan drug designation for QRX003 in Netherton Syndrome	10-21	RE
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome	10-21	AQ
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million	10-13	AQ
Top Premarket Decliners	10-13	MT
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $16.450005 million in funding	10-10	CI
Top Midday Gainers	10-10	MT
Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement	10-10	MT
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million	10-10	AQ
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome	09-09	AQ
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome	08-21	AQ
Quoin Pharmaceuticals Ltd. Appoints Sally Lawlor as Chief Financial Officer, Effective August 18, 2025	08-18	CI
Quoin Pharmaceuticals Names Sally Lawlor as Finance Chief	08-18	MT
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy	08-18	AQ
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton	08-12	AQ
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	08-07	CI
Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update	08-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Filters